0S90 Stock Chart & Stats
€0.09
-€0.02(-10.95%)
At close: 4:00 PM EST
€0.09
-€0.02(-10.95%)
Day’s Range― - ―
52-Week Range€0.09 - €0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€2.36K
Enterprise Value€86.52
Total Cash (Recent Filing)€58.27M
Total Debt (Recent Filing)€60.23M
Price to Earnings (P/E)―
Beta-2.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,832,457
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)13.24
Price to Sales (P/S)22.21
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market OpportunityManagement highlighted the large commercial opportunity for tamibarotene in RARA-positive HR-MDS, with a market opportunity of ~$1.6Bn, >$800MM in RARA positive patients.
Therapeutic PotentialTamibarotene would be the first targeted therapy for the patient population, addressing the ~50% of patients with RARA overexpression.
Trial ContinuationThe SELECT-MDS-1 Phase 3 trial has passed an interim futility analysis, indicating the trial should continue without modification.
Bears Say
Clinical Trial FailureThe Phase 3 SELECT-MDS-1 trial did not achieve its primary endpoint of complete response rate, leading to the decision to remove tamibarotene from valuation.
Financial InstabilityThe failure to meet the primary endpoint in the SELECT-MDS-1 trial triggers an event of default under the secured loan agreement with Oxford Finance LLC.
Stock Valuation DeclineThe stock traded down about 86% in the aftermarket, reflecting a significant decline in valuation.
Syros Pharmaceuticals News
0S90 FAQ
What was Syros Pharmaceuticals’s price range in the past 12 months?
Syros Pharmaceuticals lowest stock price was €0.09 and its highest was €0.09 in the past 12 months.
What is Syros Pharmaceuticals’s market cap?
Syros Pharmaceuticals’s market cap is €2.36K.
When is Syros Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Syros Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Syros Pharmaceuticals overvalued?
According to Wall Street analysts Syros Pharmaceuticals’s price is currently Overvalued.
Does Syros Pharmaceuticals pay dividends?
Syros Pharmaceuticals does not currently pay dividends.
What is Syros Pharmaceuticals’s EPS estimate?
Syros Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syros Pharmaceuticals have?
Syros Pharmaceuticals has 26,832,457 shares outstanding.
What happened to Syros Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Syros Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:0S90
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syros Pharmaceuticals
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Technical Analysis
Biodexa Pharmaceuticals
―
Q/C Technologies
―
―
Scinai Immunotherapeutics
―
Oragenics
―